Duality Biologics, an ADC partner of BeiGene and BioNTech, files for Hong Kong IPO
Clinical-stage antibody-drug conjugate startup Duality Biologics has filed for an initial public offering in Hong Kong, where there have been only …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
